

CURRICULUM VITAE

Personal Status



Name: Ji-Youn Han

Present Address (at work):

Center for Lung Cancer, National Cancer Center
323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408,
South Korea

Tel : 82-31-920-1154

Fax : 82-31-920-2587

E-mail: jymama@ncc.re.kr

Educational Background

- 1983-1989 College of Medicine, the Catholic University of Korea
Graduated in February, 1989 with the M.D. degree
- 1993-1995 Post-Graduated School, College of Medicine,
the Catholic University of Korea
Awarded the degree of M.M.S. in Internal Medicine
- 1995-1998 Post-Graduated School, College of Medicine,
the Catholic University of Korea
Awarded the degree of Ph.D. in Internal Medicine
Subject: The relationship between cisplatin-induced apoptosis and
p53, bcl-2, and bax expression in human lung cancer cells

Business Background

- 1989-1993 Internship and Resident training in the Department of Internal
Medicine, St. Mary's Hospital, College of Medicine, the Catholic
University of Korea
- 1994-1995 Fellow of the Department of Internal Medicine, Division of
Oncology, Kangnam St. Mary's Hospital, College of Medicine,
the Catholic University of Korea
- 1996-1998 Instructor of the Department of Internal Medicine, Division of
Oncology, St. Paul's Hospital, College of Medicine, the Catholic
University of Korea
- 1999-Aug 2001 Assistant Professor of the Department of Internal Medicine,

Division of Oncology, Kangnam St. Mary's Hospital, College of Medicine, the Catholic University of Korea

Sep 2001-May-2007 Senior Investigator, Lung Cancer Branch, National Cancer Center

Sep 2003-Aug 2004 Visiting Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology University of Texas M. D. Anderson Cancer Center, Houston, TX, U.S.A.

June 2007-Oct 2014 Chief, Lung Cancer Branch, National Cancer Center

Aug 2010-Dec 2017 Head, Lung Cancer Center, National Cancer Center

Aug 2012-Oct 2014 Head, Division of Translational & Clinical Research I, National Cancer Center

Oct 2014-Mar 2016 Head, Division of Convergence Technology, National Cancer Center

Oct 2015-Mar 2016 Head, Cancer Genomics Branch, National Cancer Center

Mar 2016-present Head, Division of Precision Medicine and Cancer Informatics, National Cancer Center

Mar 2016-presnet Head, Precision Medicine Branch, National Cancer Center

Dec 2016-Apr 2017 Member, Presidential Advisory Council on Science & Technology

Korean Medical License No & start date: 39378, Feb/28/1989

GCP Training Experience

05 Aug 2016 GCP training by The collaborative Institutional Training Initiative(CITI) program at the University of Miami

13 Oct 2014 Good Clinical Practice_CITI Program, Korea
[Completion Report No. K-2014-14280039]

08 Jan 2013 ICH GCP eLearning

02 Dec 2010 GCP for Investigational Site Staff from Pfizer Partner Learning Solution

28~29 Jan 2010 Investigator meeting in Seoul, Korea

15 April 2009 Investigator meeting in National Cancer Center.

Academic Activity

Korean association of Internal Medicine: active member (since 1994)
Korean Cancer Association: active member (since 1994)

International Association for the Study of Lung Cancer: active member (since 2001)
American Society of Clinical Oncology: active member (since 2002)
American Association for Cancer Research: active member (since 2002)

Major publications (during recent 5 years)

1. Kim HS, Lee JH, Nam SJ, Ock CY, Moon JW, Yoo CW, Lee GK, **Han JY**. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. *J Thorac Oncol*. 2018 Jan 31. pii: S1556-0864(18)30034-0. doi: 10.1016/j.jtho.2018.01.008. [Epub ahead of print]
2. Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, **Han JY**, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harrington S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN. Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. *Clin Cancer Res*. 2017 Sep 15;23(18):5406-5415.
3. Lee Y, **Han JY**, Moon SH, Nam BH, Lim KY, Lee GK, Kim HT, Yun T, An HJ, Lee JS. Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status. *Cancer Res Treat*. 2017 Jan 6. doi: 10.4143/crt.2016.522. [Epub ahead of print]
4. Lee Y, Lee KH, Lee GK, Lee SH, Lim KY, Joo J, Go YJ, Lee JS, **Han JY**. Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Non-Adenocarcinomatous Non-Small Cell Lung Cancer. *Cancer Res Treat*. 2017 Jan 13. doi: 10.4143/crt.2016.546. [Epub ahead of print]
5. **Han JY**, Lee GK, Lim KY, Lee YJ, Nam BH, Lee JS. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. *Cancer Res Treat*. 2017 Jul;49(3):678-687.
6. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, **Han JY**, Bordogna W, Golding S, Zeaiter A, Ou SI. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2016 Dec;34(34):4079-4085.
7. Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi

- M, Chu Q, Hida T, **Han JY**, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*. 2016 Oct 14. pii: S1470-2045(16)30508-3.
8. Shin DH, Lee D, Hong DW, Hong SH, Hwang JA, Lee BI, You HJ, Lee GK, Kim IH, Lee YS, **Han JY**. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. *Oncotarget*. 2016 Sep 8. doi: 10.18632/oncotarget.11913. [Epub ahead of print]
 9. **Han JY**, Choi JJ, Kim JY, Han YL, Lee GK. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. *BMC Cancer*. 2016 Aug 12;16:627.
 10. Lee H, Jeon S, Seo JS, Goh SH, **Han JY**, Cho Y. A novel strategy for highly efficient isolation and analysis of circulating tumor-specific cell-free DNA from lung cancer patients using a reusable conducting polymer nanostructure. *Biomaterials*. 2016 Sep;101:251-7.
 11. **Han JY**, Lee KH, Kim SW, Min YJ, Cho E, Lee Y, Lee SH, Kim HY, Lee GK, Nam BH, Han H, Jung J, Lee JS. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors. *Cancer Res Treat*. 2016 May 3. doi: 10.4143/crt.2016.058. [Epub ahead of print]
 12. **Han JY**, Kim HY, Lim KY, Hwangbo B, Lee JS. A phase II study of nintedanib in patients with relapsed small cell lung cancer. *Lung Cancer*. 2016 Jun;96:108-12.
 13. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, **Han JY**, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*. 2016 Apr 9;387(10027):1540-50.
 14. **Han JY** et al. Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. *Cancer Chemother Pharmacol* 2015;75:475-83
 15. **Han JY**, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. *Lung Cancer*. 2014 Aug;85(2):161-7.

16. **Han JY**, Lee YS, Kim BC, Lee GK, Lee S, Kim EH, Kim HM, Bhak J. Whole-genome analysis of a patient with early-stage small-cell lung cancer. *Pharmacogenomics J.* 2014 Dec;14(6):503-8.
17. **Han JY** et al. Whole-genome analysis of a patient with early-stage small-cell lung cancer. *Pharmacogenomics J.* 2014;14:503-8
18. **Han JY** et al. A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy. *Pharmacogenomics J.* 2014 Feb;14(1):20-7
19. **Han JY** et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. *Lung Cancer.* 2013 Feb;79(2):137-42.
20. **Han JY** et al. A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer. *Ann Oncol.* 2012 Nov;23(11):2925-30.
21. **Han JY** et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. *J Clin Oncol.* 2012 Apr 1;30(10):1122-8

Recent Clinical Trials Experience

Principle Investigator role

1. [NCC-2017-0195] A Phase I, First –in-Human, Open-label, Dose escalation study of JNJ-61186372, a Human Bispecific EGFR and cMet antibody, in subjects with advanced non-small cell lung cancer (2017~ongoing)
2. [NCC-2017-0194] A phase II/III multicenter study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring actionable somatic mutations detected in blood (B-Fast: Blood –Frist Assay Screening Trail) (2017~ongoing)
3. [NCC-2017-0112] A randomized phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIB-IVb NSCLC with confirmed EGFRm and T790M (2017~ongoing)
4. [NCC-2017-0086] A phase III randomized, Double-blind, placebo-controlled trial of Pembrolizumab in combination with Etoposide/Platinum for the first-line treatment of subjects with extensive stage small cell lung cancer (KENOTE-

604. 2017~ongoing)
5. [NCC-2017-0123] A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS, 2017~ongoing)
 6. [NCC-2017-0020] A phase 1/1b study of MGCD516 in patients with advanced Solid Tumor malignancies (2017~ongoing)
 7. [NCC-2017-0019] A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (2017~ongoing)
 8. [NCC-2016-0281] Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy (2016~ongoing)
 9. [NCC-2016-0192] Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) (2016/10/12 ~ ongoing)
 10. [NCC-2016-0171] A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer (2016/10/31 ~ ongoing)
 11. [NCC-2016-0107] A randomized phase II study of erlotinib alone versus erlotinib plus bevacizumab for advanced non-small cell lung cancer with epidermal growth factor receptor activating mutations (2016/10/31 ~ ongoing)
 12. [NCC-2016-0056] A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer (2016 ~ 2017)
 13. [NCC-2016-0037] Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor (2016/09/29 ~ ongoing)
 14. [NCC-2016-0008] A phase IB/2, open label, dose finding study to evaluate safety,

- efficacy, pharmacokinetics and pharmacodynamics of avelumab (MSB0010718C) in combination with either crizotinib or PF 06463922 in patients with advanced or metastatic non-small cell lung cancer (2016/04/27 ~ ongoing)
15. [NCC-2015-0289] A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+non-small-cell lung cancer (2016/7/13 ~ ongoing)
 16. [NCC-2015-0218] A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) (2016~2017)
 17. [NCC-2015-0201] A phase II, multicenter, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease (2015/12/15 ~ ongoing)
 18. [NCC-2015-0145] A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) (2015/10/27 ~ ongoing)
 19. [NCC-2015-0134] A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene(AURA17) (2015/08/31 ~ ongoing)
 20. [NCC-2015-0053] A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON) (2015/07/08 ~ ongoing)
 21. [NCC-2015-0029] A Randomized Phase 3 Study of LY2835219 plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum Based Chemotherapy (2015/10/28 ~ ongoing)
 22. [NCC-2015-0010] A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic

Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC) (2015/06/29 ~ ongoing)

23. [NCC-2014-0216] Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Patients with Advanced Malignancies (2015/04/29 ~ ongoing)
24. [NCC-2014-0185] A Phase IB/II, open label, multicenter study of INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated, c-MET-amplified non-small cell lung cancer who have progressed after EGFR inhibitor treatment (2015/03/20 ~ ongoing)
25. [NCC-2014-0184] A Phase I open-label dose escalation study with expansion to assess the safety and tolerability of INC280 in patients with c-MET dependent advanced solid tumors (2015 ~ 2017)
26. [NCC-2014-0161] Phase I / II Study to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of HM61713 in NSCLC patients with EGFR mutation (2014 ~ 2017)
27. [NCC-2014-0150] A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC) (2014 ~ 2017)
28. [NCC-2014-0134] Randomized, multicenter, phase III, open label study of alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase positive advanced non-small cell lung cancer (2014/11/17 ~ ongoing)
29. [NCC-2014-0120] A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene (AURA3) (2014/09/25 ~ ongoing)
30. [NCC-2014-0097] A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib (2015/07/14 ~ ongoing)
31. [NCC-2014-0090] A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours are

- Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive (AURA2)
(2014/07/30 ~ ongoing)
32. [NCC-2014-0078] Multicenter, open-label, uncontrolled, Phase II study in advanced non-small cell lung cancer (2014/08/14 ~ ongoing)
 33. [NCC-2014-0011] n label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280A (Anti-PD-L1 antibody) compared with docetaxel in patients with non small cell lung cancer after failure with platinum-containing chemotherapy (201402/03~ongoing)
 34. [NCC-694] Randomized Phase II Study of Palliative Chemotherapy plus Controlled Low Calorie Diet with/ or without Metformin in Patients with Advanced Solid Tumors (2013/09/16~ongoing)
 35. A Phase II, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti PD-L1 Antibody) Compared with DOCETAXEL in Patients with Non Small Cell Lung Cancer after Platinum Failure (2013/09/09~ongoing)
 36. [NCC-692] An open-label, non-randomized, multicenter phase I/II trial of RO5424802 given orally to non-small cell lung cancer patients who have ALK mutation and failed crizotinib treatment (2013/08/19~ongoing)
 37. [NCC-689] Study to assess the safety, tolerability and pharmacokinetic profile of HM61713 tablet in NSCLC patients with EGFR mutation (2013 ~ 2017)
 38. [NCC-664] A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer (2013/04/05~ongoing)
 39. [NCC-683] A phase II, open-label, multicenter, randomized study to Investigate the efficacy and safety of Atezolizumab (ANTI-PD-L1 ANTIBODY) compared with Docetaxel in patients with non-small cell lung cancer after Platinum failure (2013/09/09 ~ ongoing)
 40. [NCC-647] A Prospective, Open-label, Single arm, Multicenter, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Pozotinib) as the First-line Treatment Medication in Patients with Lung Adenocarcinoma Harboring EGFR Mutations (2012~2016)
 41. [NCC-646] A Prospective, Open-label, Single-arm, Multicenter, Phase II Exploratory Trial to Evaluate the Efficacy Patients with Acquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors (2012/11/09 ~ 2014/11/17)
 42. [NCC-561] A phase II study of neo-adjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating

- mutations (2011/08/26~ongoing)
43. [NCC-574] A phase 3, randomized, double-blinded, placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib in previously treated subjects with locally advanced or metastatic, non-squamous, non-small cell lung cancer with wild-type epidermal growth factor receptor. (2011/11/17 ~2014/04/07)
 44. [NCC-554] A Phase 2, Double-Blind, Placebo-Controlled Study of IPI 504 and Docetaxel in Previously Treated Patients with Stage IIIB or IV Non-Small Cell Lung Cancer (2011/06/20 ~ 2013/09/30)
 45. [NCC-527] A Randomized phase II study of Irinotecan/ Cisplatin with or without simvastatin in chemo-naïve patients with extensive disease-small cell lung cancer (2011/03/17 ~ ongoing)
 46. [NCC-525] A phase II study of BIBF 1120 as second-line treatment for patients with small cell lung cancer (2011/01/28~2015/07/23)
 47. [NCC-489] A randomized open label phase II trial comparing BIBW2992 plus simvastatin with BIBW2992 plus best supportive care in previously treated patients with advanced (stage IIIB/IV) non-adenocarcinomatous non-small cell lung cancer (NSCLC) (2010/06/21~ongoing)
 48. [NCC-462] Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versus investigator's choice of chemotherapy following BIBW 2992 monotherapy in non-small cell lung cancer patients failing previous erlotinib or Gefitinib treatment (2010/04/19~2014/03/31)
 49. [NCC-445] Phase 2, open-label single arm study of the efficacy and safety of PF-02341066 in patients with advanced non-small cell lung cancer harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus: (2010/01/05 ~ 2016/01/29)
 50. [NCC-446] Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (Pemetrexed or Docetaxel) in patients with advanced non-small cell lung cancer (NSCLC) harboring a translocation inversion event involving the anaplastic lymphoma kinase (ALK) gene locus: (2009/12/31 ~ 2016/03/02)
 51. [NCC-433] Phase I/II study of vorinostat and gefitinib in relapsed/ or refractory patients with advanced non-small cell carcinoma (NSCLC): (2009/10/19 ~ 2014/10/10)
 52. [NCC-399] A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients: (2009/03/16 ~ 2011/12/31)

53. [NCC-376] Multicenter, randomized, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy(1199.14) (2008/12/22 ~ 2014/10/31)
54. [NCC-371] Randomized phase II study of irinotecan/cisplatin versus gemcitabine/ cisplatin as the first-line therapy followed by two different sequences of pemetrexed or docetaxel as the second or third-line therapy for patients with advanced non-small cell lung cancer (NSCLC); pharmacogenomic study for providing personalized strategy to the treatment of advanced NSCLC: (2009/02/05 ~2015/12/18)
55. [NCC-285] A phase II study of Sunitinib as a second-line treatment for patients with extensive-disease small cell lung cancer (ED-SCLC): (2007/08/20 ~2011/12/31)
56. [NCC-177] Randomized phase II trial comparing gefitinib plus simvastatin and gefitinib alone in patients with previously treated advanced non-small cell lung cancer: (2006/03/01 ~ 2009/12/31)
57. [NCC-176] A phase II study of irinotecan/cisplatin plus simvastatin in chemo-naïve patients with ED-SCLC: (2006/03/08 ~ 2009/11/31)
58. [NCC-124] Randomized Phase II study of Irinotecan plus Capecitabine compared with Irinotecan plus Cisplatin as a First Line Treatment of Patient with Advanced NSCLC: (2005/06/10 ~2008/10/31)
59. [NCC-056] Randomized phase II study of amifostine vs. epokine given during concurrent chemo-radiation therapy following irinotecan plus cisplatin chemotherapy for limited-stage small cell lung cancer (2003/05/01 ~ 2006/06/30)
60. [NCC-055] Randomized phase III study of maintenance weekly irinotecan versus no further therapy following induction chemotherapy with irinotecan plus cisplatin in patients with extensive small cell lung cancer (2003/02/27 ~ 2006/12/31)
61. [NCC-041] A randomized phase II study of irinotecan plus cisplatin for patients with advanced IIIB or IV non-small cell lung cancer; sequence effect on PK/PK & toxicity profile (2002/09/12 ~2003/12/31)
62. [NCC-032] A Phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV non-small cell lung cancer previously treated with non-platinum based chemotherapy (2002.03.01 ~2004.09.30)
63. [NCC-031] A Phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV non-small cell lung cancer (2002.03.01 ~ 2003.02.28)
64. [NCC-023] A Phase II study of irinotecan plus capecitabine for patients with

advanced stage IIIB or IV non-small cell lung cancer previously treated with chemotherapy (2001.12.01 ~ 2003.11.30)

65. [NCC-016] A Phase II study of docetaxel plus capecitabine for patients with advanced stage IIIB or IV non-small cell lung cancer previously treated with platinum based chemotherapy (2001.11.01 ~ 2003.10.31)
66. [NCC-015] A Phase II study of docetaxel plus capecitabine for patients with advanced stage IIIB or IV non-small cell lung cancer (2001.11.01 ~ 2003.10.31)
67. [NCC-014] Phase II study of Irinotecan plus Cisplatin (CP) followed by twice daily thoracic radiation therapy (TDTRT) concurrently with etoposide and cisplatin (EP) in patients with limited-stage (LD) small cell lung cancer (SCLC) (2001.11.01 ~ 2004.10.31)
68. [NCC-006] Phase II study of irinotecan plus cisplatin in patients with extensive-stage small cell lung cancer (2001.10.01 ~2004.09.30)

I hereby declare the above-mentioned are correct and true to the best of any knowledge.

Ji-Youn Han, M.D., Ph.D.

Center for Lung Cancer,
National Cancer Center